Skip to main content
main-content

EULAR 2021 Virtual Congress coverage

2 – 5 June 2021
News highlight

​​​​​​​Rituximab, JAK inhibitors linked to worse COVID-19 severity in RA patients

COVID-19 patient
Video highlight

COVID-19 Global Rheumatology Alliance study finds link between RA treatment and COVID-19 severity

Jeffrey Sparks and Zachary Wallace

Expert video interviews from the EULAR 2021 Virtual Congress

05-06-2021 | EULAR 2021 | Conference coverage | Video

First COVAX Registry data on COVID-19 vaccine safety for patients with RMDs

Pedro Machado presents COVID-19 vaccine safety data supporting their use for patients with rheumatic and musculoskeletal diseases.

04-06-2021 | EULAR 2021 | Conference coverage | Video

Risankizumab shows promise for PsA in the KEEPsAKE 2 trial

Andrew Östör talks about the results of KEEPsAKE 2, a phase 3 trial of risankizumab versus placebo in patients with psoriatic arthritis, and explores how the IL-23 inhibitor may impact clinical practice if approved by the regulatory authorities.

04-06-2021 | EULAR 2021 | Conference coverage | Video

RESOLVE-1 fails to meet primary endpoint for lenabasum in patients with dcSSc

Robert Spiera discusses the phase 3 RESOLVE-1 findings for lenabasum in patients with diffuse cutaneous systemic sclerosis, highlighting the possible effects of background immunosuppressive therapy on outcome.

IN FOCUS | Clinical trial updates on IL-23 inhibitors for PsA

News from the EULAR 2021 Virtual Congress

View more news from EULAR 2021 Virtual Congress


Medicine Matters conference coverage is brought to you in partnership with medwireNews


Image Credits